<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A study by Chan et al in this issue of Diabetologia (DOI: 10.1007/s00125-012-2818-4 ) reports that low plasma <z:chebi fb="0" ids="16990">bilirubin</z:chebi> levels are associated with an increased risk of <z:mpath ids='MPATH_686'>amputation</z:mpath> in patients with type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> participating in the <z:chebi fb="0" ids="5001">Fenofibrate</z:chebi> Intervention and Event Lowering in <z:mp ids='MP_0002055'>Diabetes</z:mp> (FIELD) study </plain></SENT>
<SENT sid="1" pm="."><plain>These findings raise the interesting and clinically relevant hypothesis that <z:chebi fb="0" ids="16990">bilirubin</z:chebi> protects against risk of <z:mpath ids='MPATH_686'>amputation</z:mpath> in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>This commentary considers some of the limitations associated with research aiming to define any link between circulating <z:chebi fb="0" ids="16990">bilirubin</z:chebi> levels and <z:e sem="disease" ids="C0042373" disease_type="Disease or Syndrome" abbrv="">vascular disease</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Numerous confounding factors (several of which may be present in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>) may explain why the literature regarding this potentially protective role of <z:chebi fb="0" ids="16990">bilirubin</z:chebi> remains controversial </plain></SENT>
</text></document>